MRK - Merck & Co., Inc.
62.56 -0.03 (-0.05%)
Pre-Market: 7:10AM EDT
| Previous Close | 62.89 |
| Open | 62.93 |
| Bid | 61.90 x 800 |
| Ask | 62.70 x 900 |
| Day's Range | 62.33 - 62.95 |
| 52 Week Range | 52.83 - 66.41 |
| Volume | 4,513,307 |
| Avg. Volume | 10,192,898 |
| Market Cap | 168.386B |
| Beta | 1.06 |
| PE Ratio (TTM) | 108.66 |
| EPS (TTM) | 0.58 |
| Earnings Date | Jul 27, 2018 |
| Forward Dividend & Yield | 1.92 (3.09%) |
| Ex-Dividend Date | 2018-06-14 |
| 1y Target Est | 69.44 |
Yahoo Finance Video•12 days agoFed minutes warn of rising trade risks
Yahoo Finance’s Seana Smith and Jared Blikre break down the minutes from the Fed's June meeting and the other big headlines moving stocks in midday trading Thursday.
- Investopedia•19 hours ago
Analysis: Motivating Factors Behind Pfizer’s Big Split
Pfizer, the worlds second largest pharmaceutical company, announced on Wednesday, July 11th, plans to split into three separate businesses in a major restructuring move. The Innovative Medicines division will bring in most of Pfizer’s revenue. In a press release, the company said that the growth potential for that business is strongest in part because of the aging population which will increase the demand for new medicines.
Markit•yesterdaySee what the IHS Markit Score report has to say about Merck & Co Inc.
Merck & Co Inc NYSE:MRK
- The Wall Street Journal•yesterday
[$$] Startup Producing Cell-Grown Meat Raises New Funding
and a top European meat processor are backing a startup producing beef from cattle cells, ramping up a race to transform the global meat industry with cell-culture technology. fuels a continuing effort to fulfill growing global demand for meat via a process that developers say requires a fraction of the resources used in traditional livestock and poultry production.
- Zacks•4 days ago
Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
- Zacks•4 days ago
Dow 30 Stock Roundup: Boeing Q2 Commercial Deliveries Up Y/Y, Pfizer to Reorganize
The index enjoyed a strong week of gains, boosted by expectations of a strong second quarter earnings season.
- Moody's•4 days ago
Merck Financial Services GmbH -- Moody's affirms Merck KGaA's Baa1 ratings
Moody's Investors Service, ("Moody's") has today affirmed the Baa1 long-term issuer rating of Merck KGaA (Merck). Moody's has also affirmed the ratings of Merck's short term issuer, senior unsecured Medium Term Note program and junior subordinated ratings at P-2, (P)Baa1 and Baa3 respectively.
- Zacks•5 days ago
Merck's Keytruda Gets FDA's Priority Review for Liver Cancer
The FDA grants a priority review to Merck's (MRK) label expansion filing for its key cancer drug Keytruda regarding the first-line treatment of advanced HCC.
- Investopedia•6 days ago
Merck Stock Seen Rising 12% on Faster Profit Growth
Merck & Co. Inc. ( MRK) shares have dramatically outperformed the S&P 500 this year, rising 10%. Those gains may be just the start. Analysts are looking for the stock to rise by nearly 12% higher to about $69. The analysts aren't the only ones all bulled up on the pharmaceutical company.
Markit•6 days agoSee what the IHS Markit Score report has to say about Merck & Co Inc.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $375 million.
- Business Wire•6 days ago
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Hepatocellular Carcinoma
Application Based on Monotherapy Data from Phase 2 KEYNOTE-224 Trial
- Fortune•6 days ago
After Trump Criticism, Pfizer Backtracks on Drug Price Hikes—For Now
Trump is pleased with the result of his blast.
- MarketWatch•8 days ago
Pfizer shares rise after President Trump attacks its drug price hikes
President Donald Trump criticized pharmaceutical giant Pfizer Inc. (PFE) in a Monday tweet for recently increasing the prices of many of its prescription drugs. In the tweet, which referred to Pfizer and unspecified "others," Trump said that companies were "merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere. The presidential tweet follows a Financial Times report that Pfizer raised list prices for 100 products in early July, weeks after Trump promised large price reductions, and marking the second such increase this year for Pfizer.
InvestorPlace•8 days agoJohnson & Johnson Stock Only Benefits from Big Moves That May Not Come
One of the most often used arguments in favor of owning Johnson & Johnson (NYSE:JNJ) is its diversity. Diversification in and of itself doesn’t inherently make a company worth buying into, however. J&J has maintained its stature as one of the most recognizable names (if not the most recognizable name) in the healthcare arena.
Markit•8 days agoSee what the IHS Markit Score report has to say about Merck & Co Inc.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $4.54 billion.
- CNBC•11 days ago
Cramer's lightning round: Buy Merck on its superior anti-cancer portfolio
Jim Cramer rattles off his take on callers' favorite stocks, including a drugmaker that's topping its competition.
- InvestorPlace•11 days ago
Don’t Buy Biogen Stock on the Promise of an Alzheimer’s Breakthrough
Biogen (NASDAQ:BIIB) is the hot stock of the moment thanks to success in a trial of an Alzheimer’s drug. Progress on Alzheimers makes Biogen stock worth at least a look, right? Both follow the so-called “amyloid hypothesis,” the idea that reducing amyloid plaques using monoclonal antibodies can reverse the disease.
- Zacks•11 days ago
Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.
- InvestorPlace•11 days ago
Trade of the Day: Novocure Ltd (NVCR)
To receive further updates on this Novocure Ltd (NASDAQ:NVCR) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.
- Zacks•11 days ago
Dow 30 Stock Roundup: Bell-Boeing JV's Navy Deal Win, Merck Keytruda's Priority Review
The Dow traverses a holiday-shortened week during which trading volumes remain low.
Reuters•11 days agoHitting cancer early - AstraZeneca's bid to outmanoeuvre rivals
AstraZeneca (AZN.L) suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. Soriot and his team are increasingly confident that while AstraZeneca may have lost one part of the battle for cancer market dominance, it can still win elsewhere by targeting tumours before they have spread around the body. The idea that immunotherapy may actually work best in less sick patients is logical, since the immune system's natural role is to destroy nascent tumours.
Market Realist•12 days agoLabel Expansion of Merck’s Keytruda Could Boost Revenue
In July, the FDA accepted for review Merck & Co.’s (MRK) sBLA (supplemental Biologics License Application) for Keytruda in combination with carboplatin-paclitaxel or nab-paclitaxel in the first-line setting for the treatment of individuals with metastatic squamous non-small cell lung cancer (or sNSCLC), irrespective of PD-L1 expression.
- Investopedia•12 days ago
Pfizer's Stock Ready for a 10% Rebound
Pfizer Inc. ( PFE) shares have dramatically underperformed during the past three years, rising 9.4% compared to the S&P 500's rise of nearly 31%. Options traders are also betting the stock will gain in the next few months. Pfizer has not only underperformed the broader stock market, but its valuation is among the cheapest of some of the other big pharmaceuticals.
InvestorPlace•12 days agoGo Long Pfizer Stock — It’s an Easy Pill to Swallow
Pfizer (NYSE:PFE) is a pharma/biotech dinosaur. This stock is a survivor of decades of stock market turmoils and corrections. It currently sits on a potential long-term technical breakout point on the monthly chart.
Market Realist•12 days agoHow Is Merck Positioned Financially before Q2 2018 Earnings?
Merck & Co. (MRK) generated revenues of $10.04 billion in the first quarter of 2018, which represents 6.39% growth YoY (year-over-year) and a 3.8% decline sequentially.
